CAR-T immunotherapy for lymphoma studied at UNC Lineberger receives fast-track designation from FDA
University of North Carolina Health Care SystemBased on proof-of-concept results from clinical trials at University of North Carolina Lineberger Comprehensive Cancer Center and Baylor College of Medicine, an investigational cellular immunotherapy for Hodgkin lymphoma has received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration.